Pfizer asks Anvisa to release reinforcement against Covid in children

Pfizer sent Anvisa (National Health Surveillance Agency) a request for the application of the booster dose of the childhood vaccine against Covid in the public from 5 to 11 years old.

Vaccination of this age group began in January in Brazil after, in December of last year, the agency approved the use of the pediatric immunizer in two doses.

The laboratory claims that the request was sent to Anvisa because studies indicated that the third dose of the vaccine “promotes a robust immune response”. The clinical trial included 4,500 children aged 5 to 11 years.

The US regulatory agency, the FDA, approved the application of the pediatric booster vaccine on May 17. The third dose was indicated at least five months after the second.

“The decision came after data from the Phase 2/3 clinical trial showed that a 10ug booster dose of the vaccine promotes a robust immune response with a favorable safety profile, at a time when the omicron was the prevalent variant,” he said. the laboratory in a press release this Tuesday (21).

On Sunday, the Minister of Health, Marcelo Queiroga, told Sheet that the application of the third dose in children aged 5 to 11 years still needs to be discussed by the technical area and that the scientific evidence is “very incipient”.

This is the only group for which there has not yet been an indication of a third dose of the vaccine against Covid-19 in Brazil. Only the Pfizer immunizer received authorization from Anvisa for the vaccination of children aged five years.